| 21 0.5 (2.44%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.67  |
1-year : | 28.82 |
| Resists | First : | 21.12 |
Second : | 24.67 |
| Pivot price | 18.82 |
|||
| Supports | First : | 18.63 |
Second : | 17.1 |
| MAs | MA(5) : | 20.21 |
MA(20) : | 18.85 |
| MA(100) : | 18.84  |
MA(250) : | 27.12 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 94.2 |
D(3) : | 90.2 |
| RSI | RSI(14): 65.8 |
|||
| 52-week | High : | 44.34 | Low : | 15.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZLAB ] has closed below upper band by 2.8%. Bollinger Bands are 31.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.14 - 21.21 | 21.21 - 21.28 |
| Low: | 19.93 - 20.01 | 20.01 - 20.09 |
| Close: | 20.86 - 20.98 | 20.98 - 21.11 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Mon, 06 Apr 2026
Zai Lab (NASDAQ: ZLAB) reports 5.74M ADS (57.4M ordinary shares) - Stock Titan
Mon, 06 Apr 2026
[144] Zai Lab Ltd SEC Filing - Stock Titan
Mon, 06 Apr 2026
[144] Zai Lab Ltd SEC Filing - Stock Titan
Mon, 06 Apr 2026
ZLAB (NASDAQ: ZLAB) notices proposed sale of 853 ADS; prior transfers listed - Stock Titan
Mon, 06 Apr 2026
Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative (NASDAQ:ZLAB) - Seeking Alpha
Sun, 05 Apr 2026
A Look At Zai Lab (ZLAB) Valuation After New Amgen Oncology Collaboration News - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 113 (M) |
| Shares Float | 1,020 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 30 (%) |
| Shares Short | 4,890 (K) |
| Shares Short P.Month | 3,370 (K) |
| EPS | -1.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.46 |
| Profit Margin | -38.2 % |
| Operating Margin | -54.5 % |
| Return on Assets (ttm) | -12.2 % |
| Return on Equity (ttm) | -22.6 % |
| Qtrly Rev. Growth | 17 % |
| Gross Profit (p.s.) | 0.42 |
| Sales Per Share | 4.08 |
| EBITDA (p.s.) | -1.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -151 (M) |
| Levered Free Cash Flow | -93 (M) |
| PE Ratio | -13.13 |
| PEG Ratio | 0 |
| Price to Book value | 3.24 |
| Price to Sales | 5.14 |
| Price to Cash Flow | -15.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|